Your browser doesn't support javascript.
loading
Modeling Challenges of Ebola Virus-Host Dynamics during Infection and Treatment.
Chertow, Daniel S; Shekhtman, Louis; Lurie, Yoav; Davey, Richard T; Heller, Theo; Dahari, Harel.
Afiliação
  • Chertow DS; Critical Care Medicine Department, National Institutes of Health Clinical Center, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
  • Shekhtman L; The Program for Experimental and Theoretical Modeling, Division of Hepatology, Department of Medicine, Loyola University Medical Center, Maywood, IL 60153, USA.
  • Lurie Y; Network Science Institute, Northeastern University, Boston, MA 02115, USA.
  • Davey RT; Liver Unit, Shaare Zedek Medical Center and the Hebrew University of Jerusalem, Jerusalem 9103102, Israel.
  • Heller T; Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
  • Dahari H; Translational Hepatology Unit, Liver Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Viruses ; 12(1)2020 01 16.
Article em En | MEDLINE | ID: mdl-31963118
ABSTRACT
Mathematical modeling of Ebola virus (EBOV)-host dynamics during infection and treatment in vivo is in its infancy due to few studies with frequent viral kinetic data, lack of approved antiviral therapies, and limited insight into the timing of EBOV infection of cells and tissues throughout the body. Current in-host mathematical models simplify EBOV infection by assuming a single homogeneous compartment of infection. In particular, a recent modeling study assumed the liver as the largest solid organ targeted by EBOV infection and predicted that nearly all cells become refractory to infection within seven days of initial infection without antiviral treatment. We compared our observations of EBOV kinetics in multiple anatomic compartments and hepatocellular injury in a critically ill patient with Ebola virus disease (EVD) with this model's predictions. We also explored the model's predictions, with and without antiviral therapy, by recapitulating the model using published inputs and assumptions. Our findings highlight the challenges of modeling EBOV-host dynamics and therapeutic efficacy and emphasize the need for iterative interdisciplinary efforts to refine mathematical models that might advance understanding of EVD pathogenesis and treatment.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença pelo Vírus Ebola / Ebolavirus / Interações Hospedeiro-Patógeno / Modelos Teóricos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Viruses Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doença pelo Vírus Ebola / Ebolavirus / Interações Hospedeiro-Patógeno / Modelos Teóricos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Viruses Ano de publicação: 2020 Tipo de documento: Article